Breast cancer research needs to investigate how a person's ethnicity influences their response to treatment and its outcome, according to a new Comment piece in today's Lancet (18 July) by researchers from Imperial College London.
Emerging evidence suggests that particular drugs may benefit people from one ethnic group more than others, because of differences in their genetic makeup. However, most key trials looking at treatments for breast cancer have been carried out in predominantly white populations in Europe, North America and Australasia.
Other populations might not respond to a drug in the same way as the white populations in these trials, argue the researchers writing today. They suggest that clinical trials should record participants' ethnicity and analyse whether there are differences in how patients from particular ethnic groups respond to a particular therapy.
The researchers highlight the example of a drug called trasztuzumab, which is commonly used to treat people with breast cancer that is HER-2 positive. Most studies of trasztuzumab have not reported the ethnicity of participants. However, a recent study showed that people with a particular genotype responded better than others to treatment with this drug.
The genotype in question is more common in some ethnic groups than in others, so the researchers argue that an individual's ethnicity could be a key factor in determining which treatments are most likely to benefit them.
Dr Carlo Palmieri, from the Division of Surgery, Oncology, Reproductive Biology and Anaesthetics at Imperial College London and one of the authors of the piece, said: "Everyone responds differently to treatment and it's often very difficult to predict how well someone will respond to a particular drug. However, evidence is now emerging that shows how your genes might influence whether or not a particular treatment can help you.
"There are small genetic differences between people from different ethnic backgrounds and it is really important that we find out whether these genetic differences mean that certain drugs perform well in people from certain ethnic groups but not in others. It's only by doing this that we can make sure each individual receives the best possible care," added Dr Palmieri.
Breast cancer is predominantly a disease of the economically developed world, but rates are rising rapidly in Asian and economically developing countries. Different ethnic groups have different incidences of certain kinds of breast cancer regardless of where they live. For example, there is a greater incidence of basal type breast cancer within African-American and West African populations. People's outcomes from breast cancer also vary between ethnic groups for reasons which are still not entirely clear.
Source: Imperial College London
Related stories:
Gene variant boosts risk of fatty liver disease, scientists discover
Researchers at UT Southwestern Medical Center have found that individuals who carry a specific form of the gene PNPLA3 have more fat in their livers and a greater risk of developing liver inflammation. They also found that Hispanics are more likely to carry the gene variant responsible for higher liver-fat content than African-Americans and Caucasians.
Strong association found between prevalence of low white blood count and women of African descent
Researchers from Columbia University Mailman School of Public Health and the Herbert Irving Comprehensive Cancer Center at Columbia University Medical Center, have found a strong association between women of African descent from the U.S. and Caribbean, who are otherwise healthy, and the prevalence of neutropenia, or low white blood count. Neutropenia, which is associated with race and ethnicity, has essentially been unexplained and, although thought to be benign, may affect therapy for cancer or other illnesses. Among women of African descent who develop a malignancy, this association may contribute to racial disparities in treatment and outcomes. The study findings are reported online in Blackwell Publishing Ltd.
British Journal of Hematology (August 2008).
As personalized, genomic medicine takes off, four developing countries show the way for others
Developing countries that want the benefits of cutting-edge health care possibilities based on the genetic variation of individual citizens and sub-populations need to foster the new science at home, says a major new Canadian study published today by Nature Publishing Group.
Risk of breast cancer mutations underestimated for Asian women, study shows
Oncologist Allison Kurian, MD, and her colleagues at the Stanford University School of Medicine were perplexed. Computer models designed to identify women who might have dangerous genetic mutations that increase their risk of breast and ovarian cancer worked well for white women. But they seemed to be less reliable for another ethnic group.
Scientists discover major genetic cause of colorectal cancer
About one-third of colorectal cancers are inherited, but the genetic cause of most of these cancers is unknown. The genes linked to colorectal cancer account for less than 5 percent of all cases.
Breast cancer confessions: The emotional work of disclosing a diagnosis
Women diagnosed with breast cancer shoulder the emotional burden of disclosing their diagnosis to loved ones, managing the feelings of others at precisely the time when they need support themselves, according to research to be presented at the annual meeting of the American Sociological Association (ASA).
Olympic Games: Have we reached a plateau in terms of speed?
The world-record pace for the marathon continues to improve for both men and women. For men, the record pace for the marathon is now about as fast as the record pace for the 10,000-meter run just after World War II. Today, champion athletes are running more than four times farther at speeds of well under five minutes per mile.
Minorities less likely to know about breast cancer treatment options
Nearly half of women treated for breast cancer did not know that their odds of being alive after five years are roughly the same whether they undergo mastectomy or breast conserving surgery. Minority women were even less likely to be aware of this important factor of their treatment decision, according to a study from the University of Michigan Comprehensive Cancer Center.